central nervous system

News

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

News

NeOnc Technologies' founder, chief executive and chief scientific officer Thomas Chen

NeOnc Technologies has another go at a Nasdaq listing

US biotech NeOnc Technologies has applied to list on the Nasdaq as it advances a portfolio of drugs to treat diseases affecting the CNS.

News

Seaport docks $225m for its improved neuropsychiatry drugs

After emerging from the shadows with a $100 million Series A in April, Seaport Therapeutics has moved swiftly to shore up its finances with a $225 million second round to fund the developme

News

Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.

News

AI medtech specialist Firefly lists on Nasdaq after merger

Canada's Firefly Neuroscience has completed a listing on the Nasdaq via a $45 million reverse merger with IT group WaveDancer, opening up new financing routes for its artificial intelligenc

News